1. Home
  2. MVIS vs OMER Comparison

MVIS vs OMER Comparison

Compare MVIS & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MVIS
  • OMER
  • Stock Information
  • Founded
  • MVIS 1993
  • OMER 1994
  • Country
  • MVIS United States
  • OMER United States
  • Employees
  • MVIS N/A
  • OMER N/A
  • Industry
  • MVIS Industrial Machinery/Components
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • MVIS Technology
  • OMER Health Care
  • Exchange
  • MVIS Nasdaq
  • OMER Nasdaq
  • Market Cap
  • MVIS 274.2M
  • OMER 304.9M
  • IPO Year
  • MVIS 1996
  • OMER 2009
  • Fundamental
  • Price
  • MVIS $1.14
  • OMER $4.03
  • Analyst Decision
  • MVIS Strong Buy
  • OMER Strong Buy
  • Analyst Count
  • MVIS 3
  • OMER 5
  • Target Price
  • MVIS $2.50
  • OMER $18.00
  • AVG Volume (30 Days)
  • MVIS 3.3M
  • OMER 785.6K
  • Earning Date
  • MVIS 11-06-2025
  • OMER 11-12-2025
  • Dividend Yield
  • MVIS N/A
  • OMER N/A
  • EPS Growth
  • MVIS N/A
  • OMER N/A
  • EPS
  • MVIS N/A
  • OMER N/A
  • Revenue
  • MVIS $2,584,000.00
  • OMER N/A
  • Revenue This Year
  • MVIS $47.70
  • OMER N/A
  • Revenue Next Year
  • MVIS $478.91
  • OMER $9,040.39
  • P/E Ratio
  • MVIS N/A
  • OMER N/A
  • Revenue Growth
  • MVIS N/A
  • OMER N/A
  • 52 Week Low
  • MVIS $0.80
  • OMER $2.95
  • 52 Week High
  • MVIS $1.95
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • MVIS 51.77
  • OMER 45.12
  • Support Level
  • MVIS N/A
  • OMER $4.07
  • Resistance Level
  • MVIS $1.17
  • OMER $4.20
  • Average True Range (ATR)
  • MVIS 0.05
  • OMER 0.16
  • MACD
  • MVIS -0.04
  • OMER -0.04
  • Stochastic Oscillator
  • MVIS 97.44
  • OMER 2.44

About MVIS MicroVision Inc.

Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: